Abstract: A spool has a cylindrical outer shape extending in an axial direction intersecting an upward/downward direction, the spool having an outer circumferential surface in which a plurality of annular groove portions extending in a circumferential direction are formed with a space being interposed between the plurality of annular groove portions in the axial direction, a superconducting coil being wound and accommodated inside each of the plurality of annular groove portions. A cover portion is attached to the spool so as to cover each of the plurality of annular groove portions, the cover portion and the plurality of annular groove portions forming a plurality of annular flow paths for refrigerant to cool the superconducting coil. One or more communication paths extend in parallel with the axial direction to communicate adjacent annular flow paths of the plurality of annular flow paths with each other.

Abstract: A disk drive suspension of the embodiments includes a load beam, and a flexure including a mounting portion on which a slider is mounted and overlapping with the load beam. The load beam includes a tab further extending than the mounting portion longitudinal direction of the load beam. The tab is shaped in an arc such that a central portion in a lateral direction protrudes with respect to both end portions in the lateral direction, in the load beam. Each of the both end portions includes a flat surface parallel to the lateral direction.

Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.

Abstract: Among other things, the present disclosure provides designed PNPLA3 oligonucleotides, compositions, and methods thereof. In some embodiments, provided oligonucleotide compositions provide improved single-stranded RNA interference and/or RNase H-mediated knockdown. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and/or internucleotidic linkages) or N patterns thereof, conjugation with additional chemical moieties, and/or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and/or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc.

Abstract: Among other things, the present disclosure provides technologies for altering splicing, particularly for increasing inclusion of exons in splicing products. In some embodiments, the present disclosure provides SMN2 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides chirally controlled SMN2 oligonucleotide compositions. In some embodiments, provided oligonucleotides and compositions can increase level of an exon 7-containing SMN2 splicing product and/or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of splicing-related conditions, disorders and diseases. In some embodiments, the present disclosure provides methods for treating SMN2-related conditions, disorders and diseases such as SMA (spinal muscular atrophy) and ALS (amyotrophic lateral sclerosis).

Abstract: The present disclosure pertains to the recognition that immune responses mediated by CpG oligonucleotides can be affected by the stereochemistry of modified internucleotidic linkages such as phosphorothioates. In some embodiments, the present disclosure relates to chirally controlled CpG oligonucleotide compositions comprising CpG oligonucleotides comprising multiple modified internucleotidic linkages such as phosphorothioate linkages, wherein the oligonucleotides comprise one or more CpG region motifs having defined stereochemistry patterns of chiral internucleotidic linkages. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are capable of agonizing an immune response. In some embodiments, CpG oligonucleotides comprising one or more CpG region motifs are antagonistic. Methods for making and using chirally controlled CpG oligonucleotide compositions are also described.

Abstract: A tire includes a tread portion 2. A middle land portion 7 of the tread portion 2 has a first middle lateral groove 11. The first middle lateral groove 11 includes a first groove portion 31, a second groove portion 32 inclined in the same direction as the first groove portion 31, and a third groove portion 33 located between the first groove portion 31 and the second groove portion 32 and inclined relative to a tire axial direction in a direction opposite to that of the first groove portion 31. The first groove portion 31 has a groove width increasing from the third groove portion 33 toward an outer side in the tire axial direction. The second groove portion 32 has a groove width increasing from the third groove portion 33 toward an inner side in the tire axial direction.

Abstract: A tire includes a tread portion 2. At least one middle lateral groove 10 includes first and second middle tie bars 16 and 17. First and second middle sipes 21 and 22 are provided on a ground-contact surface 15s of at least one middle block 15. The first middle sipe 21 includes a termination end 21a located on an inner side in a tire axial direction with respect to the first middle tie bar 16. The second middle sipe 22 includes a termination end 22a located on an outer side in the tire axial direction with respect to the second middle tie bar 17 and on the inner side in the tire axial direction with respect to the termination end 21a of the first middle sipe 21. On the ground-contact surface 15s of the middle block 15, no groove and no sipe are provided in a first region 23.

Abstract: The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

Abstract: Among other things, the present disclosure provides designed oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for reducing levels of transcripts. In some embodiments, the present disclosure provides technologies useful for modulating transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.

Abstract: A part of a second split-flow pipe is branched into at least a first branch pipe and a second branch pipe. A second spring check valve is disposed in the first branch pipe to open when a pressure difference between an upstream side and a downstream side of the second spring check valve in the first branch pipe becomes more than or equal to a second set pressure higher than a first set pressure. A third spring check valve is disposed in the second branch pipe to open when a pressure difference between an upstream side and a downstream side of the third spring check valve in the second branch pipe becomes more than or equal to a third set pressure higher than the first set pressure. The second branch pipe is different from the first branch pipe in terms of at least one of diameter, length, and inner volume.

Abstract: A tire includes side protectors arranged in a sidewall portion. Each of the side protectors is provided with a groove. The groove includes a first inclined groove portion inclined to a first side with respect to the tire radial direction, or a second inclined groove portion inclined to a second side opposite to the first side with respect to the tire radial direction. The side protectors include first protectors each provided with the first inclined groove portion, and second protectors each provided with the second inclined groove portion.

Abstract: A heat pipe includes an insulating hollow body located inside an outer conductor. The insulating hollow body insulates a portion of the heat pipe on an outer conductor side and a portion of the heat pipe on an inner conductor side from each other. The heat pipe has a plurality of sections each connecting a corresponding one of a plurality of connection conductors to the insulating hollow body. The heat pipe further includes a communication path connecting portions of the heat pipe to each other to cause the plurality of sections to be in communication with each other. Each of the portions is connected to a corresponding one of the plurality of connection conductors.

Abstract: Among other things, the present disclosure provides designed DMD oligonucleotides, compositions, and methods of use thereof. In some embodiments, the present disclosure provides technologies useful for repairing mutant DMD transcripts by skipping exon 51, so that the transcript can be translated into an internally truncated but at least partially functional Dystrophin protein variant. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) DMD transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as muscular dystrophy, including but not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.

Abstract: Among other things, the present disclosure provides C9orf72 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides methods for treating C9orf72-associated conditions, disorders or diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia.

Abstract: Among other things, the present disclosure provides oligonucleotides, compositions, and methods for preventing and/or treating various conditions, disorders or diseases. In some embodiments, provided oligonucleotides comprise nucleobase modifications, sugar modifications, internucleotidic linkage modifications and/or patterns thereof, and have improved properties, activities and/or selectivities. In some embodiments, the present disclosure provides oligonucleotides, compositions and methods for HTT-related conditions, disorders or diseases, such as Huntington's disease.

Abstract: A superconducting magnet apparatus includes a first superconducting coil centered around an axis extending in a direction intersecting with a vertical direction and a refrigerant circulation circuit through which refrigerant circulates. The refrigerant circulation circuit includes a first cooling pipe path in thermal contact with the first superconducting coil, an upper pipe path arranged above the first cooling pipe path, a lower pipe path arranged below the first cooling pipe path, and a connection pipe path that connects the upper pipe path and the lower pipe path to each other. The first cooling pipe path includes a first storage portion where refrigerant is stored.

Abstract: A superconducting magnet includes a superconducting coil, a coolant container, a radiation shield, a first pipe, a second pipe, a refrigerator, and a connection pipe. The refrigerator is fixed to seal a tip end of the second pipe, and is inserted in the second pipe to define a flow path of a coolant between the refrigerator and the second pipe. The connection pipe makes the interiors of the first pipe and the second pipe communicate with each other inside a vacuum container. The connection pipe includes a first connection portion connecting to the first pipe and a second connection portion connecting to the second pipe. The second connection portion is located between the vacuum container and the radiation shield.

Abstract: A load beam includes a pair of flange bending parts including first bending parts, and a second bending part extending in a width direction. A first cross-section part extends in the width direction of the load beam passing through welding parts. The first cross-section part is warped up toward the flange parts. A second cross-section part extends in the width direction passing through a different position from that of the welding parts. The second cross-section part has a lesser height difference as compared to the first cross-section part. A die is used when bending the second bending part. The die includes a first relief part including a first inclined surface and a second relief part including a second inclined surface in both sides of the supporting surface.

Abstract: Among other things, the present disclosure provides designed DMD oligonucleotides, compositions, and methods of use GC thereof. In some embodiments, the present disclosure provides technologies useful for repairing mutant DMD transcripts by skipping exon 51 or exon 53, so that the transcript can be translated into an internally truncated but at least partially functional Dystrophin protein variant. In some embodiments, the present disclosure provides technologies useful for modulating DMD transcript splicing. In some embodiments, provided technologies can alter splicing of a dystrophin (DMD) DMD transcript. In some embodiments, the present disclosure provides methods for treating diseases, such as muscular dystrophy, including but not limited to Duchenne muscular dystrophy, Becker's muscular dystrophy, etc.